Cargando…
Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1
The use of recombinant viral vectors expressing T. gondii antigens is a safe and efficient approach to induce immune response against the parasite and a valuable tool for vaccine development. We have previously protected mice from toxoplasmosis by immunizing the animals with an adenovirus expressing...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654925/ https://www.ncbi.nlm.nih.gov/pubmed/23690999 http://dx.doi.org/10.1371/journal.pone.0063201 |
_version_ | 1782269794674802688 |
---|---|
author | Mendes, Érica Araújo Fonseca, Flavio G. Casério, Bárbara M. Colina, Janaína P. Gazzinelli, Ricardo Tostes Caetano, Braulia C. |
author_facet | Mendes, Érica Araújo Fonseca, Flavio G. Casério, Bárbara M. Colina, Janaína P. Gazzinelli, Ricardo Tostes Caetano, Braulia C. |
author_sort | Mendes, Érica Araújo |
collection | PubMed |
description | The use of recombinant viral vectors expressing T. gondii antigens is a safe and efficient approach to induce immune response against the parasite and a valuable tool for vaccine development. We have previously protected mice from toxoplasmosis by immunizing the animals with an adenovirus expressing the protein SAG1 (AdSAG1) of T. gondii. We are now looking for ways to improve the vaccination strategy and enhance protection. One limitation of homologous vaccinations (sequential doses of the same vector) is induction of anti-vector immune response that blocks cell transduction, restricts transgene expression and, consequently, compromises the overall outcome of vaccination. One way to avert the effects of anti-vector response is to use different viruses in prime and boost (heterologous vaccination). Bearing this in mind, we generated a modified Vaccinia Virus Ankara encoding SAG1 (MVASAG1), to be tested as boost agent after prime with AdSAG1. Although minor differences were observed in the magnitude of the anti-SAG1 immune response induced by each vaccination protocol, the heterologous immunization with AdSAG1 followed by MVASAG1 resulted in improved capacity to control brain cyst formation in a model of chronic toxoplasmosis in C57BL/6 mice. |
format | Online Article Text |
id | pubmed-3654925 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-36549252013-05-20 Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1 Mendes, Érica Araújo Fonseca, Flavio G. Casério, Bárbara M. Colina, Janaína P. Gazzinelli, Ricardo Tostes Caetano, Braulia C. PLoS One Research Article The use of recombinant viral vectors expressing T. gondii antigens is a safe and efficient approach to induce immune response against the parasite and a valuable tool for vaccine development. We have previously protected mice from toxoplasmosis by immunizing the animals with an adenovirus expressing the protein SAG1 (AdSAG1) of T. gondii. We are now looking for ways to improve the vaccination strategy and enhance protection. One limitation of homologous vaccinations (sequential doses of the same vector) is induction of anti-vector immune response that blocks cell transduction, restricts transgene expression and, consequently, compromises the overall outcome of vaccination. One way to avert the effects of anti-vector response is to use different viruses in prime and boost (heterologous vaccination). Bearing this in mind, we generated a modified Vaccinia Virus Ankara encoding SAG1 (MVASAG1), to be tested as boost agent after prime with AdSAG1. Although minor differences were observed in the magnitude of the anti-SAG1 immune response induced by each vaccination protocol, the heterologous immunization with AdSAG1 followed by MVASAG1 resulted in improved capacity to control brain cyst formation in a model of chronic toxoplasmosis in C57BL/6 mice. Public Library of Science 2013-05-15 /pmc/articles/PMC3654925/ /pubmed/23690999 http://dx.doi.org/10.1371/journal.pone.0063201 Text en © 2013 Mendes et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Mendes, Érica Araújo Fonseca, Flavio G. Casério, Bárbara M. Colina, Janaína P. Gazzinelli, Ricardo Tostes Caetano, Braulia C. Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1 |
title | Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1 |
title_full | Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1 |
title_fullStr | Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1 |
title_full_unstemmed | Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1 |
title_short | Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1 |
title_sort | recombinant vaccines against t. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing sag1 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654925/ https://www.ncbi.nlm.nih.gov/pubmed/23690999 http://dx.doi.org/10.1371/journal.pone.0063201 |
work_keys_str_mv | AT mendesericaaraujo recombinantvaccinesagainsttgondiicomparisonbetweenhomologousandheterologousvaccinationprotocolsusingtwoviralvectorsexpressingsag1 AT fonsecaflaviog recombinantvaccinesagainsttgondiicomparisonbetweenhomologousandheterologousvaccinationprotocolsusingtwoviralvectorsexpressingsag1 AT caseriobarbaram recombinantvaccinesagainsttgondiicomparisonbetweenhomologousandheterologousvaccinationprotocolsusingtwoviralvectorsexpressingsag1 AT colinajanainap recombinantvaccinesagainsttgondiicomparisonbetweenhomologousandheterologousvaccinationprotocolsusingtwoviralvectorsexpressingsag1 AT gazzinelliricardotostes recombinantvaccinesagainsttgondiicomparisonbetweenhomologousandheterologousvaccinationprotocolsusingtwoviralvectorsexpressingsag1 AT caetanobrauliac recombinantvaccinesagainsttgondiicomparisonbetweenhomologousandheterologousvaccinationprotocolsusingtwoviralvectorsexpressingsag1 |